CAIX-targeted PET/CT in Solid Tumors

Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.

Sex

All

Minimum age

18 Years

Inclusion Criteria:

* Participants with suspected malignant solid tumors or patients with newly diagnosed or recurrent/metastatic malignant solid tumors confirmed by histopathology;
* Age of 18 years and above, both male and female are eligible;
* The ECOG PS score for physical condition in the Eastern Cancer Collaboration Group is 0-1 points;
* Research participants voluntarily sign informed consent forms or have their parents/children/legal guardians sign informed consent forms, and are able to complete the trial according to the requirements of the research protocol.

Exclusion Criteria:

* Participants with severe liver and kidney dysfunction and cardiac dysfunction;
* Participants with severe obesity, claustrophobia, or other reasons who are unable to undergo PET scans;
* Pregnant or lactating women;
* Other situations that researchers believe should be excluded and documented.

• BACKGROUNDNie P, Li B, Luo L, Hou F, Zhang N, Yang H, Huang X, Zhu Z, Ma S, Wu T, Xie J, Zhang M, Yang G, Wang Z. A prospective head-to-head comparison of 18F-NYM005 PET/CT and 18F-FDG PET/CT in diagnosing renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2026 Jul;53(8):5002-5012. doi: 10.1007/s00259-026-07841-2. Epub 2026 Mar 20. PMID 41857358
• BACKGROUNDYan X, Zheng G, Wang J, Liu M, Chen J, Xie Y, Fu C, Zhang Y, Zhu W, Huo L. [68Ga]Ga-NY104 PET/CT for the detection of clear cell renal cell carcinoma in presurgical patients with renal masses (NYCRPS): a prospective, single-centre, phase II study. Eur J Nucl Med Mol Imaging. 2026 Jul;53(9):5356-5364. doi: 10.1007/s00259-026-07896-1. Epub 2026 Apr 23. No abstract available. PMID 42020811
• BACKGROUNDChen K, Cheng S, Shi J, Liu R, Wu Y, Zheng X, Song X, Zhang Y, Liu L, Wei Z, Wang Q, Li X, Dong Z, Liu Y, Yang H, Lan X, Qin C, Jiang D, Wang K, Zhang X. CA9-Targeted PET Imaging for Noninvasive Discrimination of Clear Cell Renal Cell Carcinoma and Associated Tumor Biological Features. Adv Sci (Weinh). 2026 Jul 20:e76622. doi: 10.1002/advs.76622. Online ahead of print. PMID 42473996
• BACKGROUNDMcDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget. 2012 Jan;3(1):84-97. doi: 10.18632/oncotarget.422. PMID 22289741
• BACKGROUNDLau J, Lin KS, Benard F. Past, Present, and Future: Development of Theranostic Agents Targeting Carbonic Anhydrase IX. Theranostics. 2017 Sep 26;7(17):4322-4339. doi: 10.7150/thno.21848. eCollection 2017. PMID 29158829
• BACKGROUNDvan Kuijk SJ, Yaromina A, Houben R, Niemans R, Lambin P, Dubois LJ. Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. Front Oncol. 2016 Mar 29;6:69. doi: 10.3389/fonc.2016.00069. eCollection 2016. PMID 27066453